Compare DOMO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | EDIT |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 206.0M |
| IPO Year | 2018 | 2016 |
| Metric | DOMO | EDIT |
|---|---|---|
| Price | $2.51 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $11.15 | $4.92 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $317,044,000.00 | $31,937,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $2.56 | $1.18 |
| 52 Week High | $18.49 | $4.54 |
| Indicator | DOMO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 65.88 |
| Support Level | N/A | $2.42 |
| Resistance Level | $5.39 | $3.17 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 0.75 | 85.19 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.